{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:41:25Z","timestamp":1790260885948,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.lungcan.2020.09.026","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T18:14:59Z","timestamp":1601662499000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients"],"prefix":"10.1016","volume":"150","author":[{"given":"Nicola","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sajjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Nosotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.09.026_bib0005","series-title":"GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Bray - 2018 - CA: a Cancer journal for Clinicians","author":"Global cancer statistics","year":"2018"},{"issue":"7","key":"10.1016\/j.lungcan.2020.09.026_bib0010","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/crj.12938","article-title":"Current treatments and trials in malignant pleural mesothelioma","volume":"12","author":"Bibby","year":"2018","journal-title":"Clin. Respir. J."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.026_bib0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.09.026_bib0020","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"the immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.09.026_bib0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2020.09.026_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.026_bib0035","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"E. Van Brummelen, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.09.026_bib0040","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"Supplement_5","key":"10.1016\/j.lungcan.2020.09.026_bib0045","volume":"30","author":"Popat","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2020.09.026_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215452","article-title":"Targeting immune-related biological processes in solid tumors: we do need biomarkers","volume":"20","author":"Pagni","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2020.09.026_bib0060","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.21037\/tlcr.2020.02.01","article-title":"How asbestos and other fibers cause mesothelioma","volume":"9","author":"Gaudino","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.026_bib0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.026_bib0070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.lungcan.2020.09.026_bib0075","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.lungcan.2020.09.026_bib0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.026_bib0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.lungcan.2020.09.026_bib0090","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.026_bib0095","first-page":"1157","article-title":"Role of evaluating tumorinfiltrating lymphocytes, programmed death1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedres","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.09.026_bib0105","article-title":"WHO classification of tumours of the lung, Pleura, Thymus and heart, international agency for research on Cancer","author":"Travis","year":"2015","journal-title":"International Academy of Pathology"},{"key":"10.1016\/j.lungcan.2020.09.026_bib0110","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"12","key":"10.1016\/j.lungcan.2020.09.026_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144923","article-title":"The contrasting role of p16Ink4A patterns of expression in neuroendocrine and non-neuroendocrine lung tumors: a comprehensive analysis with clinicopathologic and molecular correlations","volume":"10","author":"Fusco","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.lungcan.2020.09.026_bib0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/his.14106","article-title":"Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma","author":"Fuchs","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.lungcan.2020.09.026_bib0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/his.13165","article-title":"Recurrent NAB2-STAT6 gene fusions and oestrogen receptor-alpha expression in pulmonary adenofibromas","volume":"70","author":"Fusco","year":"2017","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.026_bib0135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2020.09.026_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14589","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ebiom.2019.01.052","article-title":"Specific V-ATPase expression sub-classifies IDHwt lower-grade gliomas and impacts glioma growth in vivo","volume":"41","author":"Terrasi","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.026_bib0150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1186\/s12885-018-4851-2","article-title":"Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up","volume":"18","author":"Invernizzi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2020.09.026_bib0155","series-title":"Applied Survival Analysis: Regression Modeling of Time-to-Event Data","author":"Hosmer","year":"2011"},{"issue":"5","key":"10.1016\/j.lungcan.2020.09.026_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2019.10.122","article-title":"Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma","volume":"159","author":"de Perrot","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"9","key":"10.1016\/j.lungcan.2020.09.026_bib0165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2020.09.026_bib0170","article-title":"Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms","author":"Blessin","year":"2020","journal-title":"Cell. Oncol. Dordr. (Dordr)"},{"issue":"17","key":"10.1016\/j.lungcan.2020.09.026_bib0175","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1002\/cam4.2580","article-title":"The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.026_bib0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2020.09.026_bib0185","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.026_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2020.02.141","article-title":"Mesothelioma in the age of \u201cOmics\u201d: before and after the Cancer genome Atlas","author":"Severson","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.lungcan.2020.09.026_bib0200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational profiling of malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.09.026_bib0205","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"the genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030636X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030636X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:11Z","timestamp":1759236251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022030636X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"alternative-id":["S016950022030636X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.026","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}